Liraglutide — deep research file

Published · Researched 2026-09-21

Slug: liraglutide · Category: Metabolic & Weight Loss Researched: 2026-09-20 (PDT). Social layer: Threads + Facebook Groups primary; Instagram queried (no usable owner content in this pass).

1. Overview

• Maker: Novo Nordisk.
• What it is: First-generation once-daily GLP-1 receptor agonist injection; the original commercial GLP-1, now largely superseded by weekly semaglutide and tirzepatide but still prescribed and actively community-discussed.
• Two brand lines:
  • Victoza — FDA-approved January 2010 as adjunct for type 2 diabetes (1.2 mg or 1.8 mg daily). EMA-approved 2009.
  • Saxenda — FDA-approved December 23, 2014 for chronic weight management (titrated to 3.0 mg daily) in adults with BMI ≥30, or ≥27 with a weight-related comorbidity. EMA-approved 2015. Also indicated ages 12+ with obesity.
• 2026 version / patent landscape (as of September 2026): The molecule is entering its generic-competition phase.
  • Teva launched the first AB-rated generic Saxenda on August 28, 2025 (first generic GLP-1 indicated for weight loss; Optum Rx bulletin).
  • Additional generic liraglutide marketing start dates listed by Drugs.com: Cipla USA (Feb 25, 2026), Orbicular (Feb 26, 2026), Biocon Pharma (Mar 27, 2026).
  • Generic liraglutide in the Victoza (diabetes) presentation has been available since 2024 (Teva FDA approval June 2024).
  • DrugPatentWatch (Sept 2026): core US patent protection runs into the 2026 period, though some listed patents (e.g., cardiovascular-use claims) stretch further; FDA regulatory exclusivity has expired.
  • Since the FDA/FTC crackdowns on compounded semaglutide and tirzepatide, some 503A/503B-style clinics now market compounded liraglutide as the legal fallback (e.g., JourneyLite, ~Jul 2026).

2. Social standing

Platform pulse: Modest but real and current. Liraglutide no longer drives viral weight-loss content — weekly sema/tirz dominate — but it holds a durable "legacy drug still in use" niche. Facebook Groups are the highest-signal surface: the group "Victoza journey" (260 members) had fresh posts within the last 72 hours as of 2026-09-20, i.e., people are still initiating Victoza today.

Group consensus:

• It's the budget/insurance-fallback GLP-1: prescribed when coverage or coupons make it cheaper than semaglutide/tirzepatide.
• Daily injection is the accepted trade-off and the single most-cited drawback.
• Side-effect onboarding support (nausea, fatigue, sleep) dominates group traffic — classic new-starter support dynamics, same as sema/tirz groups.
• With 2025–2026 generic entrants, expectations of falling prices are widespread but anecdotal; nobody in the sampled threads quoted an actual generic price.

Verified quotes (attributed by platform + context):

• Threads, verified physician @drpalana (Cesar Palana MD), 2025-05-10: "Liraglutide (Saxenda)… Yes, this one's a GLP-1 too — but it's often cheaper than semaglutide or tirzepatide, especially if your patient has coverage or coupons."
• Threads, verified physician @dr.alo (Dr. Alo), 2025-01-17, comparison chart of approved obesity meds: lists Liraglutide at 4.7% weight loss, Semaglutide at 11–12%, Tirzepatide at 12–13%. (Note: this chart's 4.7% figure differs from the published SCALE mean; see trial data in §4.)
• Facebook Group "Victoza journey", 2026-09-17 (post, 13 comments): "Anyone else experience nausea and vomiting?? I just did my first shot last night and today have been hell. Any pointers of how to get through it??"
• Facebook Group "Victoza journey", 2026-09-20 (post, 6 comments): "Is anyone else super tired all the time?"
• Facebook Group "Victoza journey", 2026-09-15: "Took first dose tonight can not sleep I am all over the place. This happen to anyone? Ugh I got a 10 hour shift in a few hours 😢"
• Facebook Group "Victoza journey", 2026-09-16: "Would victoza mess with my menstrual cycle?"

Praise (recurring): cheaper access with coverage/coupons; long safety track record (oldest GLP-1); daily routine works as habit-building for some.

Complaints (recurring): daily injection burden; nausea/vomiting during titration; fatigue; sleep disruption; weaker weight loss vs newer weeklies.

Viral moments: None found for liraglutide specifically in this pass — no viral before/after or controversy threads; social energy is support-group chatter, not influencer content.

3. Social validation — Tier 2

Tier: Tier 2 — Facebook Groups (highest-signal, live posts Sept 2026) + Threads (two verified physician posts). Instagram queried via cross-platform search; no verifiable owner content returned in this pass → Instagram weak, flagged.

Named sources and what each proves:

• Facebook Group "Victoza journey" (id 1518375475382939, ~260 members, https://facebook.com/groups/1518375475382939/) — proves active, current (Sept 2026) real-world use and the side-effect support consensus. Recent-posts fetch returned posts from 2026-09-14 through 2026-09-20.
• Facebook Group "Semaglutide Tirzepatide Liraglutide Discussions" (id 665537783056501, ~284 members) — proves liraglutide is still grouped alongside the newer agents in community taxonomy, not retired.
• Facebook Group "Glp-1 medications weight loss support" (id 24251766854427808, ~913 members) — proves the broader GLP-1 support-pool liraglutide users draw from.
• Facebook Group "GLp--1 Weight loss medication, Recipes Support, Motivation and Idea group" (id 851665093590710, ~252 members) — same umbrella signal.
• Threads @drpalana (verified MD, 2025-05-10) — proves the "cheaper with coverage/coupons" professional framing.
• Threads @dr.alo (verified, 2025-01-17) — proves liraglutide's efficacy ranking vs sema/tirz in professional comparison content.
• Web layer: GoodRx, Medical News Today, ro.co cost guides; Optum Rx new-generics bulletin (Aug 2025); Drugs.com generic availability table; DrugPatentWatch (Sept 2026) — for pricing/patent facts only, not social signal.

4. Key specs

5. Pricing — DATED

• Saxenda US list price: $1,349.02/month (30-day supply). Source: PCMA/PBM "Same Drug, Different Prices" GLP-1 chart (published Sept 2024; observed 2026-09-20). Corroborated by ro.co cost guide (crawled ~Sept 15, 2026) and AK Twisted Wellness cost guide.
• Victoza US list price: $543.51/month (per PCMA chart, Sept 2024; observed 2026-09-20).
• GoodRx: average retail $1,645.78 for most common version; as low as $372.45 with GoodRx coupon (~77% off). (GoodRx Saxenda page; crawled ~Feb 2026; observed 2026-09-20.)
• Pen needles: ~$60 per box of 100 (60¢/needle), per AK Twisted Wellness cost guide (observed 2026-09-20).
• Compounded liraglutide (gray-market street price): JourneyLite (Illinois bariatric clinic) advertises $198 first month / $298 ongoing monthly for compounded liraglutide (clinic blog, ~Jul 2026; observed 2026-09-20). This is a commercial provider listing, not independently verified.
• Generic Saxenda (Teva, launched Aug 28, 2025): retail price not published in sources checked → UNVERIFIED. Drugs.com generic-availability table lists marketing start dates but no prices.
• Marketplace (Facebook/online reseller) used/unopened range: none observed → UNVERIFIED / no data in this pass.

6. What is included / what else is needed

• Included: Saxenda ships as a carton of five 3 mL prefilled pens (6 mg/mL; 18 mg per pen). (GoodRx: "only available as a carton of five 3ml pens.")
• NOT included: pen needles — separate prescription, purchased separately. Sharps container and alcohol swabs not included either.

7. Support reality

• Manufacturer support: Novo Nordisk runs SaxendaCare® patient support program. A 2020 PMC real-world study found SaxendaCare® enrollees had better dose persistence and numerically greater weight loss than non-enrollees.
• Savings programs: Novo Nordisk savings cards / cost estimator (888-809-3942) exist for eligible commercially-insured patients; savings programs were referenced across the cost guides (GoodRx, ro.co).
• Warranty/returns: N/A as pharmaceuticals go — prescription drugs are generally non-returnable once dispensed; no community report of warranty-style claims surfaced. (General pharmacy-policy knowledge, not a community-verified report.)
• Support reputation: Positive in-program signal (SaxendaCare® persistence data); in groups, users lean on peer support for titration side effects rather than reporting formal support interactions.

8. Community verdict

Liraglutide is the affordable workhorse GLP-1: groups confirm it's still being started today, valued for its coverage-friendly price point and long safety record, but the daily shot and weaker weight loss (~8 kg mean in SCALE vs 15%+ on the weeklies) make it a second-line or budget option, not a destination. Generic and compounded entrants in 2025–2026 are reshaping its value story, but actual generic street prices remain unverified.

9. Regulatory & safety status

• FDA: Victoza approved January 2010 (type 2 diabetes); Saxenda approved December 23, 2014 (weight management, ages 12+).
• EMA: Victoza 2009; Saxenda 2015.
• Safety signals (plain language): Black-box warning for thyroid C-cell tumors — seen in rats and mice; it's unknown whether liraglutide causes these tumors in humans. Pancreatitis (inflamed pancreas) has been reported — severe persistent stomach pain needs prompt care. Also gallbladder problems, kidney issues from heavy vomiting/diarrhea (dehydration), low blood sugar when combined with insulin or sulfonylureas, and serious allergic reactions. Common side effects: nausea, vomiting, diarrhea, constipation, decreased appetite — worst during the first weeks of dose increases, which is exactly what the "Victoza journey" group posts describe.
• Not for: people with a personal or family history of medullary thyroid cancer or MEN 2.

10. Missing-image views + UNVERIFIED points log

• Images captured (5 of 8): all real, verified photos (verified 200, JPEG):
  • img/liraglutide-hero.jpg — hand holding Saxenda pen, dose window at 0.6 mg, box behind (LifeMD/Saxenda side-effects page, images.ctfassets.net).
  • img/liraglutide-side.jpg — two Saxenda pens on white, label side (MaNaDr medical-notes page).
  • img/liraglutide-box.jpg — Saxenda 5×3 mL retail carton with one pen in front (throughwithchew.com retailer product photo, Shopify CDN).
  • img/liraglutide-owner.jpg — real owner-style photo: Victoza 3-pen box, pen with visible plunger, and 6 mm pen needles on a table (mariruddy.com personal blog).
  • img/liraglutide-top.jpg — alternate angle: Victoza box + pen from above (musclebond.is shop product photo).
• Missing views (3): rear, detail (close-up of dose dial), scale. No traceable owner-in-use injection photo, no box-back/rear shot, and no with-object-for-scale shot found; not synthesized — left honestly empty.
• UNVERIFIED points:
  1. Actual retail price of Teva generic Saxenda (launched Aug 28, 2025) — launch confirmed, price not published.
  2. Any Facebook Marketplace / reseller used-price range for Saxenda or Victoza pens — no data observed.
  3. JourneyLite $198/$298 compounded pricing — provider marketing copy only, not independently verified.
  4. Current 2026 Victoza list price — $543.51 figure is from a September 2024 PBM chart; no 2026-dated confirmation found.
  5. Instagram owner-content presence — none returned in this pass; not evidence of absence.
  6. The Threads chart figure of 4.7% weight loss for liraglutide conflicts with the published SCALE mean of ~8% (8.4 kg); quoted as-posted, flagged as inconsistent.

Not medical advice. This is research material only; consult a qualified clinician.

Sources

• Source: facebook.com — retrieval date not recorded